Arcus Biosciences, Inc.

RCUS

CIK 0001724521 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$33M
↑+26.9% +$7Mvs FY2024 (Q4)
Gross Profit
$33M
↑+26.9% +$7Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
49/100
  • Profitability
    0ROIC -48.3% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.36 (above 1.5 = solid)
  • Leverage
    92D/E 0.16 (under 0.5 = conservative)
  • Efficiency
    1Asset Turnover 0.22x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +26.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -546.2% · trend -161.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2M
investment in PP&E
Stock-based comp (TTM)
$60M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.14B
everything owned
Total liabilities
$695M
everything owed
Stockholders' equity
$631M
shareholder claim
Net debt
$-123M
Net cash position ($123M)

Recent performance · 37 quarters

Revenue↑+26.9% +$7M
$33M
Net Income↓-46.7% -$43M
$-135M
Free Cash Flow↑+0.0% +$0
$-1M
Operating Margin↓-327.4pts
-546.2%

Drill down